Intensity Therapeutics, Inc. · NASDAQ:INTS
Intensity Therapeutics — CTOS Annual Meeting 2024
11 slides from Intensity Therapeutics's conference presentation, 2024
Slide 1: INVINCIBLE-3 Study
INVINCIBLE-3 STUDY A MULTICENTER, RANDOMIZED, PHASE 3 STUDY OF INTRATUMORAL INT230-6 COMPARED TO STANDARD OF CARE THERAPY IN SELECTED METASTATIC SOFT Content of this presentation is the property of the author, licensed by CTOS. Permission is required to reuse. TISSUE SARCOMAS Christian Meyer, MD PhD
Slide 2: INT230-6 is a Novel Intratumoral Agent Consisting of Cisplatin, Vinblastine and SHAO
INT230-6 is a Novel Intratumoral Agent Consisting of Cisplatin, Vinblastine and SHAO Designed for Dense, Stromal, Fatty Tumors Cisplatin & Vinblastine are co-formulated in a fixed ratio with SHAO, a tissue dispersion and cell penetration amphiphilic agent SHAO Cisplatin Vinblastine (10mg/mL) 0.5mg/m
Slide 3: Intratumoral INT230-6 is Diffused and Absorbed Into Tumors
Intratumoral INT230-6 is Diffused and Absorbed Into Tumors Human pancreatic cancer in mouse model Tumor dose is set by the longest diameter or volume from 3 dimensions Injections made to center of tumor over 90 seconds Cytotoxics + dye in H2O INT230-6 + dye in H2O Water-based drug NOT absorbed: sign
Slide 4: INT230-6 Achieves Significant Tumor Killing with One or Two Doses in Multiple Types of Cancers
INT230-6 Achieves Significant Tumor Killing with One or Two Doses in Multiple Types of Cancers Breast cancer tumors fully resected 3.9 cm invasive ductal cancer: Grade 3 given 2 injections 4.4 cm invasive lobular cancer: Grade 2 single injection May 6 May 13 May 20 May 27 June 16 Injection #1: Injec
Slide 5: INT230-6 Produces Immune Infiltration in Non-immunogenic Cancers such as sarcoma
Multiplex IHC Staining From Matched Pair Biopsies Using Monotherapy INT230-6 Produces Immune Infiltration in Non-immunogenic Cancers such as sarcoma Day 0 Day 28 Pre-Dose Post 2 Doses At 28 days, post two doses, there is an cancer increased presence of CD3, CD4 and CD8 T- cells (green, yellow and or
Slide 6: Phase 1/2 Refractory or Metastatic Cancer Study (IT-01)
Phase 1/2 Refractory or Metastatic Cancer Study (IT-01) Overall survival increases with higher INT230-6 doses as monotherapy relative to the sarcoma patient’s presenting total tumor burden (TTB) Exploratory analysis indicates that treating a higher percentage of the patient’s total tumor burden corr
Slide 7: Sarcoma Results
Sarcoma Results The sarcoma diagnoses of the Phase 2 patients included liposarcoma, pleomorphic sarcoma, leiomyosarcoma, chondrosarcoma, osteosarcoma (chondroid syringoma), myofibroblastic, osteosarcoma, Kaposi sarcoma and chordoma Efficacy: • INT230-6 extended mOS in refractory sarcoma subjects by
Slide 8: Phase 3 Trial Design For INT230-6 in Soft Tissue Sarcoma (STS)
Phase 3 Trial Design For INT230-6 in Soft Tissue Sarcoma (STS) Schema for 2 or 3 line nd rd n = 333 Randomized, open-label, multicenter, Phase 3 Radiographic disease Enrollment Criteria INT230-6 Monotherapy progression is determined • Subtypes: unresectable or • INT230-6 every 14 days, 5 sessions us
Slide 9: Dosing Information: A Session's Dose is Set by the Number of Tumors Being Injected
Dosing Information: A Session’s Dose is Set by the Number of Tumors Being Injected • Dosing must be performed with ultrasonography or CT guidance • INT230-6 will be injected with the largest tumors possible first, through to the smallest • The oncologist and interventional radiologist determine whic
Slide 10: Phase 3 Trial Information
Phase 3 Trial Information: Countries that have authorized the study: US, Canada, Australia, Europe (France, Germany, Italy, Poland, Spain): Total sites expected: up to 69 Key Inclusion Criteria: • who had disease progression prior to study enrollment following standard therapies, which must have inc
Slide 11: Acknowledgements
Acknowledgements Toronto Sarcoma Program, Princess Margaret Cancer Center Author: Albiruni Abdul Razak, MB BCh, BAO, LRCP & SI Intensity Therapeutics Lewis H. Bender, MS, MA, MBA – Intensity Therapeutics Kimberly A. Guedes – Intensity Therapeutics Brian E. Schwartz, n/a – Intensity Therapeutics Pres